Impact Biomedical (NYSEAMERICAN:IBO) Director Sells $32,500.00 in Stock

Impact Biomedical Inc. (NYSEAMERICAN:IBO) Director Jason Grady sold 50,000 shares of the stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $0.65, for a total transaction of $32,500.00. Following the completion of the transaction, the director owned 250,182 shares of the company’s stock, valued at $162,618.30. This represents a 16.66% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Impact Biomedical Trading Up 1.8%

Impact Biomedical stock opened at $0.57 on Friday. Impact Biomedical Inc. has a 52 week low of $0.36 and a 52 week high of $2.25. The stock has a market cap of $60.14 million, a price-to-earnings ratio of -0.15 and a beta of 6.37. The company’s 50-day moving average price is $0.50 and its two-hundred day moving average price is $0.56.

Impact Biomedical Company Profile

Impact Biomedical, Inc (“IBIO”) currently is a holding company operating mainly through our majority owned subsidiary, Global BioLife, Inc, which was incorporated on April 14, 2017. The Company is committed to both funding research and developing intellectual property portfolio. We currently focus on research in three main areas: (i) development of a universal therapeutic drug platform; (ii) a new sugar substitute; and (iii) a multi-use fragrance. IBIO discovers, confirms, and patents unique science and technologies which can be developed into new offerings in human healthcare and wellness in collaboration with external partners through licensing, co-development, joint ventures, and other relationships.